Zoetis Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Zoetis stock.
View analyst ratings for Zoetis or view top-rated stocks.

9 brokers have issued 12-month price objectives for Zoetis' stock. Their ZTS stock forecasts range from $208.00 to $264.00. On average, they expect Zoetis' share price to reach $229.75 in the next year. This suggests a possible upside of 31.9% from the stock's current price.
View analysts' price targets for Zoetis or view top-rated stocks among Wall Street analysts.

Zoetis' stock was trading at $244.03 at the start of the year. Since then, ZTS shares have decreased by 28.6% and is now trading at $174.21.
View the best growth stocks for 2022 here.

Zoetis is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Zoetis.

Zoetis will be holding an earnings conference call on Thursday, August 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings results on Thursday, May, 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.10. The company earned $2 billion during the quarter, compared to the consensus estimate of $1.98 billion. Zoetis had a trailing twelve-month return on equity of 49.62% and a net margin of 26.27%. The firm's quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.26 earnings per share.
View Zoetis' earnings history.

Zoetis announced a quarterly dividend on Thursday, May 19th. Shareholders of record on Thursday, July 21st will be paid a dividend of $0.325 per share on Thursday, September 1st. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Wednesday, July 20th.
View Zoetis' dividend history.

Zoetis(NYSE:ZTS) pays an annual dividend of $1.30 per share and currently has a dividend yield of 0.76%. Zoetis does not yet have a strong track record of dividend growth. The dividend payout ratio of Zoetis is 29.82%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zoetis will have a dividend payout ratio of 22.57% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
View Zoetis' dividend history.

Zoetis updated its FY 2022 earnings guidance on Thursday, May, 19th. The company provided EPS guidance of $4.99-$5.09 for the period, compared to the consensus earnings per share estimate of $5.16. The company issued revenue guidance of $8.22 billion-$8.38 billion, compared to the consensus revenue estimate of $8.42 billion.

50 employees have rated Zoetis CEO Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among Zoetis' employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

Some companies that are related to Zoetis include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of ZTS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Zoetis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Park National Corp OH (0.02%) and Insight Wealth Strategies LLC (0.00%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis.

ZTS stock was sold by a variety of institutional investors in the last quarter, including Insight Wealth Strategies LLC. Company insiders that have sold Zoetis company stock in the last two years include Catherine A Knupp, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Roman Trawicki, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis or view top insider-selling stocks.

ZTS stock was purchased by a variety of institutional investors in the last quarter, including Park National Corp OH.
View insider buying and selling activity for Zoetis or or view top insider-buying stocks.

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZTS stock can currently be purchased for approximately $174.21.

Zoetis (NYSE:ZTS) has a market capitalization of $81.99 billion and generates $7.78 billion in revenue each year. The company earns $2.04 billion in net income (profit) each year or $4.36 on an earnings per share basis.

Zoetis employs 12,100 workers across the globe.

Zoetis was founded in 2012.

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for Zoetis is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.